Skip to main content

Table 1 Population, intervention, comparator and outcome selection (PICOS) criteria

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Population Adults (aged (≥18 years) with episodic or chronic migraine with or without aura (where specified, International Headache Society diagnostic criteria, Headache Classification Committee of the International Headache Society, 2013 [34])
Intervention/comparators Lasmiditan (50 mg, 100 mg, 200 mg)
Rimegepant (75 mg)
Ubrogepant (25 mg, 50 mg, 100 mg)
Outcomes • Pain freedom at 2 hours (pain reduced from moderate or severe to none without use of rescue medication within 2 hours)
• Pain relief at 2 hours (pain reduced from moderate or severe to none or mild without use of rescue medication within 2 hours)
• Pain relief at 1 hour (pain reduced from moderate or severe to none or mild without use of rescue medication within 1 hour)
• MBS freedom at 2 hours (freedom from the MBS, as identified by the patient, from the associated symptoms of nausea, phonophobia and photophobia)
• Sustained pain freedom over 24 hours (pain freedom at 2 hours, sustained for 24 hours, without the use of rescue medication or a second dose of study medication)
• Discontinuation due to AEs
Study design Randomised controlled trials
  1. AE adverse event, MBS most bothersome symptom